Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | -2,401,198 | 6.51 M | 12.17 M | 11.29 M | |
2022 | -2,856,504 | 7.05 M | 14.46 M | 13.37 M | |
2021 | 736.36 M | 8.7 M | 9.36 M | 8.5 M | |
2020 | 889.48 K | 7.99 M | 1.38 M | 465.17 K | |
2019 | 77.3 K | -4,931,384 | 1.88 M | 6.17 M | 5.38 M |